

Since this was a retrospective study using clinical routine treatment or diagnostic medical records, the Chang Gung Medical Foundation Institutional Review Board approved the waiver of the participant's consent. All methods were carried out under relevant guidelines and regulations.

Chang Gung Medical Foundation

Institutional Review Board

199, TUNG HWA NORTH ROAD,

TAIPEI, TAIWAN, 10507

REPUBLIC OF CHINA

Tel: (03) 3196200

Fax: (03) 3494549

Date 2022/10/17

Protocol Title: Acute cholangitis: the difference between malignant biliary obstruction and choledocholithiasis

IRB No. : 202201601B0

Principal Investigator(s): TSOU, YUNG-KUAN

Executing Institution: Linkou

Duration of Approval: From 2022/10/17 To 2023/1/16

Version/Date of documents:

(1)Protocol: 2022/10/10 version 1

(2)Chinese Synopsis: 2022/10/10 Version1

(3)Informed Consent Form: The IRB approves the waiver of the participants' consent.

(4)Case Report Form: 2022/10/10 Version 1

The IRB reviewed and determined that it is expedited review according to Case research or cases treated or diagnosed by clinical routines.

However, this does not include HIV positive cases.

Date of Approval: 2022/10/17

Frequency of Continuing Report: Once a year

※The research will expire on 2023/01/16. Please submit the final report to the IRB for review within three months after the expiration of the trial research. For extension of the trial period, please submit the amendment and a continuing report two months before the expiration.

The IRB is organized and operates in accordance with Good Clinical Practice and the applicable laws and regulations.



Tsang-Tang Hsieh, MD
Chairman
Institutional Review Board